Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's third consecutive day of gains.
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman
Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...
US Stock Market Update: Dow plunges over 650 pts, S&P retreats from record high; Walmart slumps 6%
The Dow Jones Industrial Average (DJIA) fell as much as 677.4 points, or 1.5 per cent, to 43,950.2, while the S&P 500 dropped ...
Medscape3h
Dupilumab Under FDA Priority Review for Bullous Pemphigoid
Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
Regeneron Pharmaceuticals, Inc. (REGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Hosted on MSN9h
Biogen Stock Is Mutating Into a Value Play
Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...
Medpage Today on MSN17h
Semaglutide Tied to Small Risk of Potentially Blinding Eye Condition
The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...